Qube Research & Technologies LTD Cel Sci Corp Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.11 - $1.85 $12,217 - $20,362	-11,007 Reduced 99.48%	58 $0
Q1 2024 May 14, 2024	BUY	$1.63 - $3.08 $1,349 - $2,550	828 Added 8.09%	11,065 $21,000
Q4 2023 Feb 13, 2024	BUY	$1.07 - $3.07 $10,951 - $31,421	10,235 Added 511750.0%	10,237 $27,000
Q3 2023 Nov 13, 2023	BUY	$1.17 - $2.86 $2 - $5	2 New	2 $0
Q4 2022 Feb 14, 2023	BUY	$1.99 - $3.52 $957 - $1,693	481 Added 1.59%	30,662 $72,000
Q3 2022 Nov 14, 2022	BUY	$3.09 - $5.23 $93,259 - $157,846	30,181 New	30,181 $93,000
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $45,864 - $88,707	-17,777 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$3.93 - $7.7 $225,519 - $441,856	-57,384 Reduced 76.35%	17,777 $70,000
Q4 2021 Feb 01, 2022	BUY	$7.1 - $12.82 $533,643 - $963,564	75,161 New	75,161 $534,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.